Mutual of America Capital Management LLC Purchases 405 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Mutual of America Capital Management LLC increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 26.7% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,924 shares of the biopharmaceutical company’s stock after purchasing an additional 405 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Alnylam Pharmaceuticals were worth $529,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in ALNY. Souders Financial Advisors increased its stake in shares of Alnylam Pharmaceuticals by 1.0% in the 2nd quarter. Souders Financial Advisors now owns 3,512 shares of the biopharmaceutical company’s stock worth $853,000 after acquiring an additional 36 shares in the last quarter. Huntington National Bank raised its holdings in Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 45 shares during the last quarter. Lindbrook Capital LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 11.1% during the third quarter. Lindbrook Capital LLC now owns 570 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 57 shares in the last quarter. V Square Quantitative Management LLC lifted its stake in Alnylam Pharmaceuticals by 21.9% during the 2nd quarter. V Square Quantitative Management LLC now owns 334 shares of the biopharmaceutical company’s stock valued at $81,000 after acquiring an additional 60 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its holdings in Alnylam Pharmaceuticals by 54.2% in the second quarter. Allspring Global Investments Holdings LLC now owns 259 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 91 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have issued reports on ALNY shares. Scotiabank raised their target price on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a research report on Friday, November 1st. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, November 19th. Barclays lifted their price target on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a report on Friday, November 1st. Cantor Fitzgerald reissued a “neutral” rating and issued a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Finally, Needham & Company LLC restated a “buy” rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $298.09.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $253.35 on Wednesday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The firm’s fifty day moving average is $272.74 and its 200 day moving average is $239.37. The company has a market cap of $32.68 billion, a price-to-earnings ratio of -96.70 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to analysts’ expectations of $532.91 million. The company’s quarterly revenue was down 33.3% on a year-over-year basis. During the same quarter last year, the company earned $1.15 EPS. Sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.